- Home
- UTHR
as 03-25-2025 10:41am EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 14.4B | IPO Year: | 1999 |
| Target Price: | $388.25 | AVG Volume (30 days): | 622.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 24.64 | EPS Growth: | 24.38 |
| 52 Week Low/High: | $221.53 - $417.82 | Next Earning Date: | 04-30-2025 |
| Revenue: | $2,877,400,000 | Revenue Growth: | 23.63% |
| Revenue Growth (this year): | 11.7% | Revenue Growth (next year): | 6.50% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thompson Tommy G | UTHR | Director | Mar 24 '25 | Sell | $318.80 | 2,500 | $796,990.50 | 8,480 | |
| PATUSKY CHRISTOPHER | UTHR | Director | Mar 19 '25 | Sell | $310.89 | 5,000 | $1,553,584.58 | 1,000 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Mar 10 '25 | Sell | $319.24 | 1,900 | $607,784.75 | 400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Mar 3 '25 | Sell | $312.82 | 9,442 | $2,944,187.16 | 400 | |
| Thompson Tommy G | UTHR | Director | Feb 28 '25 | Sell | $318.34 | 2,500 | $795,837.75 | 8,480 | |
| KURZWEIL RAY | UTHR | Director | Feb 28 '25 | Sell | $318.79 | 15,000 | $4,755,151.44 | 14,025 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Feb 24 '25 | Sell | $360.66 | 9,400 | $3,389,151.55 | 400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Feb 18 '25 | Sell | $370.15 | 9,500 | $3,523,612.18 | 400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Feb 10 '25 | Sell | $347.81 | 9,855 | $3,429,764.93 | 400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Feb 3 '25 | Sell | $351.97 | 9,300 | $3,286,275.68 | 400 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Investor's Business Daily
5 days ago
Investing Action Plan: Anduril Industries, United Therapeutics, Barstool In Miami
StockStory
6 days ago
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
StockStory
8 days ago
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
MT Newswires
8 days ago
UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating
Insider Monkey
12 days ago
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment?
StockStory
14 days ago
2 Value Stocks on Our Watchlist and 1 to Ignore
Argus Research
16 days ago
Weekly Stock List
Business Wire
22 days ago
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.